title: Short- and Longterm Glycemic Control of Streptozotocin-Induced Diabetic Rats Using Different Insulin Preparations.
abstract: The chemical induction of diabetes with STZ has gained popularity because of the relative ease of rendering normal animals diabetic. Insulin substitution is required in STZ-rats in long-term studies to avoid ketoacidosis and consequently loss of animals. Aim of the present studies was to test different insulin preparations and different ways of administration in their ability to reduce blood glucose in STZ-induced diabetic rats. Single dosing of the long-acting insulin analogue glargine was able to dose-dependently reduce blood glucose over 4 h towards normoglycemia in STZ-treated rats. However, this effect was not sustained until 8 h post injection. A more sustained glucose-lowering effect was achieved using insulin-releasing implants. In STZ-rats, 1 insulin implant moderately lowered blood glucose levels 10 days after implantation, while 2 implants induced normoglycemia over the whole day. According to the glucose-lowering effect 1 as well as 2 insulin implants significantly reduced HbA1c measured after 26 days of implantation. In line with the improved glucose homeostasis due to the implants, urinary glucose excretion was also blunted in STZ-treated rats with 2 implants. Since diabetic nephropathy is one of the complications of longterm diabetes, renal function was characterized in the STZ-rat model. Increases in creatinine clearance and urinary albumin excretion resemble early signs of diabetic nephropathy. These functional abnormalities of the kidney could clearly be corrected with insulin-releasing implants 27 days after implantation. The data show that diabetic STZ-rats respond to exogenous insulin with regard to glucose levels as well as kidney parameters and a suitable dose of insulin implants for glucose control was established. This animal model together with the insulin dosing regimen is suitable to address diabetes-induced early diabetic nephropathy and also to study combination therapies with insulin for the treatment of type 1 diabetes.
authors.affiliation: Department of CardioMetabolic Diseases Research, Boehringer Ingelheim Pharma GmbH&Co.KG, Biberach an der Riss, Germany.
authors.forename: Gerd
authors.initials: G
authors.lastname: Luippold
authors.affiliation: Department of CardioMetabolic Diseases Research, Boehringer Ingelheim Pharma GmbH&Co.KG, Biberach an der Riss, Germany.
authors.forename: Jessica
authors.initials: J
authors.lastname: Bedenik
authors.affiliation: Department of CardioMetabolic Diseases Research, Boehringer Ingelheim Pharma GmbH&Co.KG, Biberach an der Riss, Germany.
authors.forename: Anke
authors.initials: A
authors.lastname: Voigt
authors.affiliation: Department of Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH&Co.KG, Biberach an der Riss, Germany.
authors.forename: Rolf
authors.initials: R
authors.lastname: Grempler
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000187:drug effects; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy* / Q000473:pathology; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy*; D003928:Diabetic Nephropathies / Q000097:blood / Q000473:pathology; D004339:Drug Compounding; D005951:Glucose Tolerance Test; D006801:Humans; D007328:Insulin / Q000008:administration & dosage* / Q000737:chemistry; D000069036:Insulin Glargine / Q000008:administration & dosage; D049528:Insulin, Long-Acting / Q000008:administration & dosage* / Q000737:chemistry; D007668:Kidney / Q000187:drug effects / Q000473:pathology; D008297:Male; D051381:Rats
chemical_list: D001786:Blood Glucose; D007328:Insulin; D049528:Insulin, Long-Acting; D000069036:Insulin Glargine